Skip to main content
VIRXinactive

Viracta Therapeutics, Inc.

Biopharma developer (SEC filing verified)·Phase 1·CEO: California Table
Oncology

VIRX evidence brief

What we can confirm

BioSniper Score:
3.7 / 10
Lead Asset:
nana-val (Phase 1)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 3.7 / 10 · Lead Asset: nana-val (Phase 1)
BioSniper AIPage evidence connected

Prepared research question

What matters most for VIRX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

nana-val (Phase 1)

Next Catalyst

—

Tracking 1 pipeline candidate · 1 clinical trial for Viracta Therapeutics, Inc..

Run Viracta Therapeutics, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Viracta Therapeutics, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is Viracta Therapeutics, Inc.'s lead drug candidate?

Viracta Therapeutics, Inc.'s most advanced tracked candidate is nana-val (Phase 1) for EBV-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and other EBV+ solid tumors.

Who is the CEO of Viracta Therapeutics, Inc.?

California Table is the chief executive officer of Viracta Therapeutics, Inc. (VIRX).

What therapeutic areas does Viracta Therapeutics, Inc. focus on?

Viracta Therapeutics, Inc. develops therapies across Oncology.

923 companies304,840 SEC filings22,637 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.